CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer
- 10 December 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (35), 4308-4316
- https://doi.org/10.1200/jco.2012.42.7336
Abstract
We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer–specific death, and risk of a second breast cancer in women with a first breast cancer. From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer–specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor–positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer–specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor–positive first breast cancer only. Among women with estrogen receptor–positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer–specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.Keywords
This publication has 20 references indexed in Scilit:
- CHEK2*1100delC homozygosity is associated with a high breast cancer risk in womenJournal of Medical Genetics, 2011
- CHEK2 Is a Multiorgan Cancer Susceptibility GeneAmerican Journal of Human Genetics, 2004
- Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variantJournal of Medical Genetics, 2004
- CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 StudiesAmerican Journal of Human Genetics, 2004
- Mendelian randomization: prospects, potentials, and limitationsInternational Journal of Epidemiology, 2004
- Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation CarriersBreast Cancer Research and Treatment, 2004
- The CHEK2 1100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer PhenotypeAmerican Journal of Human Genetics, 2003
- Chk1 and Chk2 kinases in checkpoint control and cancerCancer Cell, 2003
- ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*International Journal of Epidemiology, 2003
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002